Navigation Links
An Aid to Tailoring Prostate Cancer Treatment
Date:5/16/2009

Study identifies factors to help decide how aggressive therapy should be

FRIDAY, May 15 (HealthDay News) -- Researchers claim to have found a way to better customize the treatment of prostate cancer.

Four risk factors that can help predict how long men could survive with metastatic prostate cancer have been identified by researchers from the Duke Comprehensive Cancer Center, who say such information would help doctors individualize treatments.

"There is a need for identification of accurate and simple-to-use prognostic factors for men with prostate cancer that has spread beyond the prostate," Andrew Armstrong, a medical oncologist at Duke and the lead investigator for the study, said in a university news release. "Our study was aimed at developing accurate predictors which may be used to assist in clinical decision making and also in planning clinical trials for men whose disease has stopped responding to hormone therapy."

By studying the records of more than 1,000 men who were taking part in a study of the chemotherapeutic drug docetaxel and its effect on metastatic prostate cancer, the researchers found four risk factors that predicted how well someone would respond to treatment:

  • The presence of cancer-related pain
  • Anemia
  • How extensively the cancer has spread to other organs
  • The progression of cancer in bone

"Using these predictors, we were able to assign patients to risk groups of good -- indicating an average survival of about two years; intermediate -- with survival of about 1.5 years; and poor -- with survival of less than a year," Armstrong said.

"By knowing a patient's prognosis and expected responses to chemotherapy, we are better able to discuss and determine whether a more- or less-aggressive treatment plan might be advisable," he said.

Another benefit is long-range knowledge, Armstrong said. Identifying men's prognoses and how they are expected to respond to treatment also would help determine whether a drug is ready for a phase 2 trial, which test a treatment that has been shown to help some people. It usually compares a newer treatment to the gold standard, or best-known treatment.

"We're eager to use this information to accurately estimate what to expect with current therapies," Armstrong said.

The findings are to be made available to those attending the American Society of Clinical Oncology's annual meeting in Orlando, Fla., in late May.

More information

The American Cancer Society has more about prostate cancer.



-- Dennis Thompson



SOURCE: Duke University, news release, May 14, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tailoring glioblastoma therapies: 1 size does not fit all
2. The Childrens Hospital of Philadelphia Receives Grant to Study Tailoring Pediatric Preventive Care to Individual Needs
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. First biomarker discovered that predicts prostate cancer outcome
5. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
6. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
7. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
8. Red wine compound shown to prevent prostate cancer
9. Barbershop Talks Cut Black Mens Prostate Cancer Risk
10. Generic prostate drug helps find high-risk cancers early
11. Finasteride unlikely to induce high grade prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
An Aid to Tailoring Prostate Cancer Treatment
(Date:4/28/2017)... LINCOLN, R.I. (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much ... Sleep Foundation (NSF), going just 19 hours without sleep can compromise motor reaction time, which ... Awareness Week, and Amica Insurance is sharing the following tips from the NSF to help ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: ... , “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on ... and Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management Association (RBMA) ... 2017-2018. The annual board election process has been in place since the RBMA was ... C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: